IBRX Stock In Spotlight: ImmunityBio Guides For 168% Revenue Surge In Q1 On ANKTIVA Momentum

The company highlighted that ANKTIVA, the interleukin-15 immunotherapy, is now authorized in five regions across 34 countries.
In this photo illustration, the ImmunityBio logo is displayed on the screen of a tablet. (Photo Illustration by Sheldon Cooper/SOPA Images/LightRocket via Getty Images)
In this photo illustration, the ImmunityBio logo is displayed on the screen of a tablet. (Photo Illustration by Sheldon Cooper/SOPA Images/LightRocket via Getty Images)
Profile Image
Shivani Kumaresan·Stocktwits
Published Apr 09, 2026   |   8:14 AM EDT
Share
·
Add us onAdd us on Google

ImmunityBio, Inc. (IBRX) announced on Thursday that it expects a first-quarter net product revenue to reach approximately $44.2 million, marking a 168% year-on-year surge. 

This performance builds on 2025 full-year net product revenue of $113 million, a 700% jump from 2024, and represents a 15% sequential increase over fourth-quarter 2025’s $38.3 million.

The company also highlighted that ANKTIVA, the interleukin-15-based immunotherapy, now holds approval or authorization in five regulatory jurisdictions, covering roughly 34 countries.

ImmunityBio stock edged 0.1% lower in Thursday’s premarket. 

Get updates to this developing story directly on Stocktwits.

Follow on Google News
Read about our editorial guidelines and ethics policy